JCEM: Prevalence of non-alcoholic fatty liver disease in patients with type 1 diabetes.

The prevalence of non-alcoholic fatty liver disease (NAFLD) is high, especially in obese and type 2 diabetes, and is expected to rise sharply in the coming decades.
recently, researchers aimed at assessing the prevalence of NAFLD in people with type 1 diabetes and exploring relevant characteristics and outcomes were published in journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases.
researchers retrieved studies on NAFLD and type 1 diabetes published in the PubMed and Embase databases by March 2020 and screened the references included in the literature.
two researchers independently sifted through the title/summary.
a researcher screened the full article.
naFLD as described in individual studies, i.e. fat degeneration and/or fibrosis.
excluded studies that did not report alternative causes of liver fat degeneration or defined NAFLD only as elevated liver enzymes.
, 919 documents met the selection criteria.
researcher used standardized tables to extract and bias to assess risk.
researchers assessed the combined prevalence using meta-analysis of random effect models, and then explored heterogeneity through subgroup analysis, meta-regression analysis, and sensitivity analysis.
the analysis was included in 20 studies published between 2009 and 2019 (n-3901).
the prevalence of NAFLD in the united countries was 19.3% (95% CI 12.3-27.5%) and increased to 22.0% in adults (95% CI was 13.9-31.2%).
magnetic resonance imaging (8.6%, 95% CI 2.1-18.6%), liver biopsy (19.3%, 95% CI 10.0-30.7%) or instantaneous elasticity Compared to the study of imaging examination (2.3%, 95% CI 0.6-4.8%), the combined prevalence of NAFLD in ultrasound (27.1%, 95% CI was 18.7-36.3%).
result, the prevalence of NAFLD in people with type 1 diabetes is high and highly dependent on the diagnostic methods used and THE definition of NAFLD.
.